# Ralf Gutzmer

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/ralf-gutzmer/

## Facts

| Field | Value |
| --- | --- |
| Citations | 41,323 |
| Field | Cutaneous Melanoma Detection and Management |
| h-index | 83 |
| i10-index | 333 |
| Last Known Institution | University Hospitals of the Ruhr-University of Bochum |
| OpenAlex ID | https://openalex.org/A5015081105 |
| ORCID iD | https://orcid.org/0000-0001-7921-2820 |
| Works | 753 |

## Researcher papers

- [Genomic correlates of response to CTLA-4 blockade in metastatic melanoma](https://scholariq.org/papers/genomic-correlates-of-response-to-ctla-4-blockade-in-metastatic-melanoma/)
- [Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial](https://scholariq.org/papers/nivolumab-versus-chemotherapy-in-patients-with-advanced-melanoma-who-progressed/)
- [Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma](https://scholariq.org/papers/adjuvant-pembrolizumab-versus-placebo-in-resected-stage-iii-melanoma/)
- [Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma](https://scholariq.org/papers/integrative-molecular-and-clinical-modeling-of-clinical-outcomes-to-pd1-blockade/)
- [Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial](https://scholariq.org/papers/treatment-with-two-different-doses-of-sonidegib-in-patients-with-locally/)
- [Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial](https://scholariq.org/papers/adjuvant-pembrolizumab-versus-placebo-in-resected-stage-iii-melanoma-eortc-1325/)
- [Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial](https://scholariq.org/papers/cemiplimab-in-locally-advanced-basal-cell-carcinoma-after-hedgehog-inhibitor/)
- [Long‐term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42‐month analysis of the phase II randomized, double‐blind BOLT study](https://scholariq.org/papers/long-term-efficacy-and-safety-of-sonidegib-in-patients-with-advanced-basal-cell/)
- [Long‐term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30‐month analysis of the randomized phase 2 BOLT study](https://scholariq.org/papers/long-term-efficacy-and-safety-of-sonidegib-in-patients-with-locally-advanced-and/)

## Researcher topics

- [Cutaneous Melanoma Detection and Management](https://scholariq.org/topics/cutaneous-melanoma-detection-and-management/)
- [Melanoma and MAPK Pathways](https://scholariq.org/topics/melanoma-and-mapk-pathways/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Nonmelanoma Skin Cancer Studies](https://scholariq.org/topics/nonmelanoma-skin-cancer-studies/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)

## Researcher university

- [University Hospitals of the Ruhr-University of Bochum](https://scholariq.org/institutions/university-hospitals-of-the-ruhr-university-of-bochum/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.